News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

The Zacks analyst is impressed by the rosy air travel demand scenario. However, the company's high debt load is a concern. Kisqali, Pluvicto Drive Novartis (NVS) Amid Competition Per the Zacks analyst ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...

"If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who currently ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Recommendation is based on the Phase III NATALEE trial, where Kisqali added to endocrine therapy (ET) significantly reduced the risk of recurrence by 25% versus ET alone across a broad population of ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization ...